Skip to main content

Geschrieben von admin am . Veröffentlicht in Uncategorised.

Privacy Policy

Privacy policy

We respect your personal data!

In the following, we describe how personal data is processed within the scope of our websites, functions and content as well as external offers (such as social media). We also describe what types of personal data are processed, to what extent and for what purpose.

1. Name and address of the data controller

The data controller within the meaning of the General Data Protection Regulation and other national data protection laws of the member states as well as other data protection regulations is:

Johann Wolfgang Goethe-Universität Frankfurt am Main

Theodor-W.-Adorno-Platz 1

60323 Frankfurt am Main

Mailing-address:
Goethe-Universität Frankfurt am Main
60629 Frankfurt

Telephone: +49-69-798-0 | Fax: +49-69-798-18383
Web: www.uni-frankfurt.de

Represented by: Prof. Dr. Thomas Oellerich

If you have any questions about the privacy policy, please contact the data protection office of the Goethe University.

Data Protection Office:
Sandra Stelzenmüller
Eschersheimer Landstraße 121
60322 Frankfurt am Main
2750 IKB-Gebäude
Telephone: +49 69 798-12238
http://www.uni-frankfurt.de/datenschutzbeauftragte
or by e-mail to  Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

2. General information on data processing
2.1. Scope of the processing of personal data

When you contact us as an interested party, we collect personal data. This happens when you contact us by e-mail or telephone or when you use the contact form in the context of existing business relationships. In these contexts, we process personal data, such as first and last name, address, email address, and telephone number.

2.2. Legal basis for the processing of personal data

If a processing of personal data is based on the consent of the data subject, Art. 6 (1) (a) of the EU General Data Protection Regulation (GDPR) serves as the legal basis. If personal data are processed in order to fulfill a contract with the data subject, Art. 6 (1) (b) GDPR serves as the legal basis. This also applies to processing operations that are necessary to carry out pre-contractual measures. If we process personal data in order to fulfill a legal obligation, Art. 6 (1) c GDPR serves as the legal basis. If the vital interests of the data subject or another natural person make it necessary to process personal data, Art. 6 (1) (d) GDPR serves as the legal basis. If we process data to protect the legitimate interests of our company or a third party and the interests, fundamental rights and freedoms of the data subject are not more important, Art. 6 (1) f GDPR serves as the legal basis for the processing.

2.3. Cooperation with data processors and third parties

If, in the course of our processing, we disclose data to other persons and companies (processors or third parties), transmit it to them or grant them access to the data, this will only be done on the basis of a legal permission (e.g. a transmission to payment service providers required for the performance of a contract pursuant to Art. 6 (1) lit. b GDPR), consent, a legal obligation or on the basis of our legitimate interests (e.g. when using agents, web hosts). If we commission third parties with the processing of data on the basis of a so-called "data processing agreement", this is done on the basis of Art. 28 GDPR.

2.4. Transfers to third countries

If we process data in a third country (i.e. outside the European Union or the European Economic Area) or if this is done in the context of using third-party services, this is only done if it is done to fulfil our (pre-)contractual obligations, on the basis of consent, due to a legal obligation or on the basis of our legitimate interests. We process data subject to legal or contractual permissions only if the requirements of Art. 44 et seq. GDPR are met: Data is therefore only processed if, for example, special guarantees exist, such as official recognition of a level of data protection corresponding to the EU (e.g. adequacy decision) or compliance with officially recognised contractual obligations (so-called standard contractual clauses).

2.5. Data deletion and storage period

As soon as the purpose of storage ceases to apply, personal data of a data subject will be deleted or its processing restricted ("blocked"). If European or national regulations, laws or other provisions to which we are subject require longer storage, the personal data will be stored in accordance with these legal provisions for longer than the original purpose intended.

2.6. Data deletion upon withdrawal

All data collected up to the point of withdrawal will be deleted immediately - unless a legal requirement requires retention.

3. Rights of the data subject

You have the right to gain access to the stored personal data.

You can obtain information from us about your stored data at any time (in accordance with Art. 15 GDPR).

You have the right to rectification.

You can request the correction of your data (in accordance with Art. 16 GDPR).

You have the right to erasure.

You can request the deletion (pursuant to Art. 17 of the GDPR) or a restriction of the processing of your data (pursuant to Art. 18 of the GDPR).

You have the right to data portability.

You can receive personal data that you have given us in a transferable format (in accordance with Article 20 of the GDPR).

You have the right to lodge a complaint.

You have the right to lodge a complaint with the competent supervisory authority (pursuant to Art. 77 DSGVO).

4. Data collection on our website
4.1. Server and log files

Our hosting provider collects the following data for statistical analysis: IP address of your computer at the time of access, date, time, retrieved content, the page from which you reached our homepage, operating system and browser.

4.2. Forms that require input (e.g. contact form)

You can fill out a contact form on our website. We store the data transmitted via the contact form from the input mask. We only process the data for the purpose of contacting you. The following data is collected: E-mail address, name, telephone number, and reason for your contact/message. The legal basis for processing the data that you transmit to us via the contact form is a (pre-)contractual obligation or your consent by transmitting your data for the purpose of contacting you. You can withdraw this consent at any time with effect for the future (informally by e-mail or post).

4.3. Mail

On our website you will find one or more e-mail addresses through which you can contact us. We store the personal data transmitted with the e-mail. We process the data only for the purpose of contacting you. The following data is collected: E-mail address, company, title, surname, first name, telephone number and reason for your contact. The legal basis for the processing of the data that you send us by e-mail is a (pre-)contractual obligation or your consent through the transmission of your data for the purpose of contacting you. You can revoke this consent at any time with effect for the future (informally by email or post).

5. Analysis and online marketing

Cookies are text files that are sent to your computer when you use websites in order to recognise it. Cookies are used to facilitate the use of websites and to make them more individual. You can set your web browser to inform you when cookies are being sent or to reject cookies. You can find information on this in the help function of your web browser (e.g. Firefox, Internet Explorer or Safari).

Our website does not use cookies or other tracking technologies.

6. Social Media: online presences and plug-ins

We maintain online presences in social networks and platforms in order to communicate with customers, interested parties and users active there and to inform them about our services. When accessing the respective networks and platforms, the terms and conditions and data processing guidelines of the respective operators apply.

7. Third-party services, tools and content

We do not use content or service offers from third parties to integrate their content and services (e.g. maps or fonts, hereinafter referred to as "content"). The prerequisite for this is that the third-party providers are aware of your IP address. We endeavour to only use content whose providers only use the IP address to deliver the content.

8. Contact with the data protection officer

Our company does have a data protection officer. You can reach him/her at the following address:
Data Protection Office:
Sandra Stelzenmüller
Eschersheimer Landstraße 121
60322 Frankfurt am Main
2750 IKB-Gebäude
Telephone: +49 69 798-12238
http://www.uni-frankfurt.de/datenschutzbeauftragte
or by e-mail to Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

Weiterlesen … Privacy Policy

  • Aufrufe: 156

Geschrieben von admin am . Veröffentlicht in Uncategorised.

testseite

Oellerich Lab
Mechanistic
Leukemia
Research

AG Oellerich
our focus
and mission

GOETHE UNIVERSITY
GOETHE UNIVERSITY

HOME

RESEARCH

OUR TEAM

NETWORK & FUNDING

PUBLICATIONS

CONTACT


Lymphoma. Leukemia.

Cell Therapy Research

Mechanistic Cancer Research:

Our mechanistic cancer research focuses on lymphoma and acute myeloid leukemia.

We combine innovative technologies such as proteomics, (functional) genomics, and molecular and cellular biology approaches to elucidate oncogenic mechanisms. To target these mechanisms, we additionally design and clinically validate innovative therapies. In lymphoma, we study the oncogenic pathways affecting B-cell receptor signaling, chromatin structure, and the tumor microenvironment. Additionally, in collaboration with Stefan Knapp (Dept. of Medicinal Chemistry, Frankfurt) we develop innovative drugs specifically targeting the newly identified oncogenic effector proteins. In AML, we currently focus on deregulated proteogenomic and metabolic programs and their therapeutic implications. More recently, we have expanded our mechanistic research program towards studying CAR-cell therapeutics with the goal to enhance their efficacy and to overcome resistance mechanisms.

Publication

Cell Therapy Research:

We elucidate the molecular pathways controlling CAR T-cell activity and study resistance mechanisms mediated by the tumor microenvironment. Our goal is to improve the efficacy of cell therapeutics, while minimizing their toxic side effects.

Clinical proteogenomics and systems biology:

In addition to our mechanistic cancer research, we have established a pipeline for the proteogenomic (multi-omics) analysis of patient-derived tumors, with a main focus on lymphoma and leukemia.

We elucidate proteomic and genomic features and integrate them to identify, so far, unresolved aspects of tumor biology. The addition of single-cell sequencing analysis furthermore allows us to link observed patterns to individual tumor cells, or cells of the tumor microenvironment.

We have established the entire value chain, including relevant patient cohorts and clinical expertise, along with innovative proteomic and genomic technologies, IT infrastructure, as well as bioinformatics for integrative multi-modal data analysis. The goal of our proteogenomics research program is to further refine the molecular classification of tumors, to elucidate their pathophysiology, to identify biomarkers predicting therapy response, and to foster the development of innovative therapies.

Publication

Bioinformatics:

To fully leverage the comprehensive proteogenomic data that we are able to acquire from large patient cohorts, we collaborate closely with the lab of DKTK professor Florian Buettner (https://mlo-lab.github.io/author/florian-buettner). Together, we pursue the development and application of novel tools and algorithms for machine-learning and artificial intelligence based multi-omics data integration. We ensure that these tools are inherently interpretable, trustworthy, and are accompanied with user-friendly implementations in order to ensure broad applicability across diverse tumor entities.


Technologies

Protein Interactome Profiling:

We have established a broad range of quantitative MS assays for the unbiased analysis of protein-protein interactions and their temporal dynamics. Our BioID/ Turbo-ID assays rely on the fusion of a protein of interest (bait) with a promiscuous biotin ligase enzyme, known as BirA*. Upon expression in living cells, this fusion protein biotinylates proximal proteins within a radius of 10-20 nanometers, covalently attaching biotin molecules to lysine residues. Subsequently, biotinylated proteins are isolated using streptavidin affinity purification, followed by elution and identification via mass spectrometry. By capturing proteins that come into close proximity with the bait protein, the BioID assay provides a comprehensive snapshot of the protein interactome within the cellular context.

Tissue/Blood Proteomics:

A well-established portfolio of proteomic workflows enables the purification of proteins from a variety of biological materials. Proteins can be isolated from cell culture models and freshly isolated tumor cells as well as from fresh frozen and formalin-fixed tissues. Recently, plasma proteomics was implemented in the lab using the fully automated pipeline for plasma protein enrichment with the Proteograph SP100 from Seer (https://seer.bio). Seer’s nanoparticle technology uses engineered nanoparticles to capture proteins across the entire dynamic range, providing an unbiased sampling of the plasma proteome.

Proximity Ligation
Assays (PLA)

The proximity ligation assay is a well-established imaging methodology which allows us to evaluate the location and interaction of two specific protein targets in situ. In short, we are able to detect whether two proteins are within a certain proximity to each other (<40nm) and through quantification of fluorescent puncta upon confocal visualization, we can evaluate and quantify interaction differences upon specific treatments or genetic modifications.

Mass Spectrometry:

Next to the molecular biology branch, our lab is home to the proteomics platform of the DKTK partner site Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI). It allocates expertise and technology predominantly to Frankfurt-based DKTK/FCI researchers, but also at other partner sites like Berlin, Heidelberg and Munich, as well as DKTK/FCI collaboration partners abroad.

Currently, the platform is running four LC/MS systems (Thermo Fisher Scientific Q-Exactive series and Orbitrap Astral) and is fully equipped with state-of-the-art instrumentation for sample preparation and a powerful IT infrastructure. The available workflows for MS-based proteomics include global protein expression profiling of model systems and clinical samples, the analysis of post-translational modifications like phosphorylation or ubiquitination, as well as protein interaction studies. Typically, these are combined with isotopic labeling techniques (SILAC, TMT) or label-free approaches for relative protein quantitation. Moreover, the platform is open for the implementation of dedicated strategies required to promote specific projects of collaboration partners from the cancer research community. Thereby, interested DKTK/FCI researchers have full access to the platform services and receive project-specific advice.

The proteomics platform engages in the mechanistic elucidation of oncogenic processes, especially in the context of lymphoma and leukemia, but also colorectal cancer, glioma, breast cancer and lung cancer. Furthermore, the activities of the platform strongly focus on the systematic characterization of well-defined patient cohorts of these cancer entities, including trial cohorts and analyzing fresh-frozen as well as FFPE tissue samples and blood plasma. To this end, the achievements of the platform i) facilitate to identify proteomic disease subtypes with prognostic and predictive relevance in highly-collaborative multi-omics projects and ii) enable the allocation of proteomic workflows to DKTK/FCI investigators for their translational cancer research.

CRISPR-Cas9-based
functional genomics :

A broad set of targeted and screening applications based on the CRISPR-Cas9 technology is applied in our laboratory to unravel cancer biology. Examples include CRISPR-Cas9-based loss/gain of function or mutant knock-in screens that we use to study oncogenic pathways and therapy resistance mechanisms in lymphoma and leukemia

Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum.

Selected Technologies:

Proximity Ligation Assay:

The proximity ligation assay is a well-established methodology in our laboratory that allows us to evaluate in situ the location and interaction of two specific protein targets. In short, we are able to detect whether two proteins are within a certain proximity to each other (<40nm) and through quantification of fluorescent puncta upon confocal visualization, we can then evaluate and quantify interaction differences upon specific treatments or genetic modifications

  • Oellerich Lab

  • Oellerich Lab

  • Oellerich Lab

  • Oellerich Lab

Weiterlesen … testseite

  • Aufrufe: 6334

Geschrieben von admin am . Veröffentlicht in Uncategorised.

Main Page

Lymphoma
Leukemia
Cell Therapy
Research

Lymphoma
Leukemia
Cell Therapy
Research

LATEST NEWS

UNIVERSITY HOSPITAL FRANKFURT

UNIVERSITY HOSPITAL FRANKFURT

Our Mission

The mission of our department is to advance cures for cancer patients through world-class clinical care and innovative research.
Therefore, we offer the full spectrum of treatments for hematological malignancies and solid cancers and are dedicated to translational and clinical research with a main focus on lymphoma, leukemia and cellular therapies

→ OELLERICH LAB

Our research laboratory, embedded within the German Cancer Consortium (DKTK) and the Frankfurt Cancer Institute (FCI), is dedicated to unraveling the intricate mechanisms underlying lymphoma and leukemia biology, along with the vision to translate our research findings into clinical advancement. Our focus is the identification of drug targets and predictive biomarkers, the elucidation of therapy resistance mechanisms, and the development of innovative therapeutic approaches, including molecular and cellular therapies. Therefore, we combine deep mechanistic research with cutting-edge technologies such as mass-spectrometry-based proteomics, functional genomics and high-resolution imaging to study innovative tumor models and patient-derived tumors.


 
 

Read more

→ SERVE LAB

Acute Myeloid Leukemia (AML) is an aggressive type of leukemia, which despite recent therapeutic progress still is fatal in the majority of cases. One important aspect of AML pathophysiology is its aggressive behavior in the bone marrow microenvironment. However, its molecular basis and metabolic mechanisms are still insufficiently understood.
Integrated into the Frankfurt Cancer Institute (FCI) and the German Cancer Consortium (DKTK), our interdisciplinary research laboratory is interested in deciphering targetable mechanisms that lead to clonal dominance and tumor expansion of AML cells. In this context, we are particularly focused on the analysis of metabolic dependencies, clonal hematopoiesis -associated genetic mutations and therapy-induced resistance mechanisms with the aim to develop novel therapeutic options

Read more

→ BRANDTS/KOSCHADE LAB

Our research lab, affiliated with the University Cancer Center Frankfurt (UCT) and the Frankfurt Cancer Institute (FCI), works at the interface of acute myeloid leukemia (AML) studying cellular and molecular mechanisms of AML maintenance and therapy resistance. Therefore, we explore the role of autophagy pathways using CRISPR/Cas9, proteomics, metabolic and flow cytometry-based assays. Investigating bone marrow adipocytes (BMAd) as the dominant population of the bone marrow microenvironment, we aim to understand the role of host autophagy pathways.
We also employ various molecular and cellular techniques looking at nongenetic adaptive pathways contributing to AML persistence during chemotherapy.
Additionally, integrating genomic data with phosphoproteomics enhances decision-making in molecular tumor boards and allows us to identify biomarkers for drug response.

Read more

→ CREMER LAB

Our research is dedicated to the translation of basic science to the clinic. Acute lymphocytic leukemia (ALL) is the second most common leukemia. Although the traditional multiagent chemotherapy regimens induce high complete remission (CR) rates, many adult patients experience relapse of their disease. Despite the breakthrough advances of antibody-based therapies, the overall long-term survival rate for patients with relapsed or refractory ALL, as well as for certain genetic subtypes is still dismal emphasizing the need for novel, targeted treatment strategies. By applying a multi-omics approach, as well as innovative screening strategies and complementing our results with clinical patient samples and data, our goal is to identify new oncogenic transcriptional networks in acute lymphoblastic leukemia (ALL) which will ultimately lead to new targeted treatment strategies for patients with this disease

Read more

→ SCHEICH LAB

Our group focuses on translational cancer research. We are dedicated to advancing knowledge in two specific research fields, lymphoid malignancies and the microbiome in cancer patients. Our overarching objective is to elucidate the fundamental mechanisms contributing to the onset of hematologic malignancies, patients' response to established therapeutic modalities and to find novel therapeutic targets. Through state-of-the art technologies such as CRISPR/Cas9 screens, functional proteomics and super resolution microscopy (dSTORM, SIM) we study lymphoma biology. Paired with the genomic and proteomic analysis of patient derived materials, we study disease development and therapy responses to ultimately improve patient outcomes.
 
 
 

Read more

→ RIEGER LAB

We focus our research on basic mechanisms that control normal and disturbed stem cell fate decisions (self-renewal, differentiation, lineage choice, quiescence, metabolism). Clonal architecture, dominance and competition of stem cells in health and disease are studied. Hematopoietic stem cells and their orchestrated differentiation into blood cell lineages are primarily studied. Eary molecular drivers of clonal dominance and their consequences on interorgan communication and disease progression must be understood for early prevention and treatment of hematologic and non-hematologic diseases.  We utilize and develop cutting-edge single cell technologies and bioinformatic analyses and apply them to stem cell systems from mice and humans. MultiOmics single cell sequencing combined with multi-color FACS sorting enable analysis of defined cell identites.

Read more

Our Mission

The mission of our department is to advance cures for cancer patients through world-class clinical care and innovative research.
Therefore, we offer the full spectrum of treatments for hematological malignancies and solid cancers and are dedicated to translational and clinical research with a main focus on lymphoma, leukemia and cellular therapies

→ OELLERICH LAB

Our research laboratory, embedded within the German Cancer Consortium (DKTK) and the Frankfurt Cancer Institute, is dedicated to unraveling the intricate mechanisms underlying lymphoma and leukemia biology, along with the vision to translate our research findings into clinical advancement. Our focus is the identification of drug targets and predictive biomarkers, the elucidation of therapy resistance mechanisms, and the development of innovative therapeutic approaches, including molecular and cellular therapies. Therefore, we combine deep mechanistic research with cutting-edge technologies such as mass-spectrometry-based proteomics, functional genomics and high-resolution imaging to study innovative tumor models and patient-derived tumors.

Read more

→ SERVE LAB

Acute Myeloid Leukemia (AML) is an aggressive type of leukemia, which despite recent therapeutic progress still is fatal in the majority of cases. One important aspect of AML pathophysiology is its aggressive behavior in the bone marrow microenvironment. However, its molecular basis and metabolic mechanisms are still insufficiently understood.
Integrated into the Frankfurt Cancer Institute and the German Cancer Consortium (DKTK), our interdisciplinary research laboratory is interested in deciphering targetable mechanisms that lead to clonal dominance and tumor expansion of AML cells. In this context, we are particularly focused on the analysis of metabolic dependencies, clonal hematopoiesis -associated genetic mutations and therapy-induced resistance mechanisms with the aim to develop novel therapeutic options

Read more

→ BRANDTS/KOSCHADE LAB

Our research lab, affiliated with the University Cancer Center Frankfurt (UCT) and the Frankfurt Cancer Institute (FCI), works at the interface of acute myeloid leukemia (AML) studying cellular and molecular mechanisms of AML maintenance and therapy resistance. Therefore, we explore the role of autophagy pathways using CRISPR/Cas9, proteomics, metabolic and flow cytometry-based assays. Investigating bone marrow adipocytes (BMAd) as the dominant population of the bone marrow microenvironment, we aim to understand the role of host autophagy pathways.
We also employ various molecular and cellular techniques looking at nongenetic adaptive pathways contributing to AML persistence during chemotherapy.
Additionally, integrating genomic data with phosphoproteomics enhances decision-making in molecular tumor boards and allows us to identify biomarkers for drug response.

Read more

→ CREMER LAB

Our research is dedicated to the translation of basic science to the clinic. Acute lymphocytic leukemia (ALL) is the second most common leukemia. Although the traditional multiagent chemotherapy regimens induce high complete remission (CR) rates, many adult patients experience relapse of their disease. Despite the breakthrough advances of antibody-based therapies, the overall long-term survival rate for patients with relapsed or refractory ALL, as well as for certain genetic subtypes is still dismal emphasizing the need for novel, targeted treatment strategies. By applying a multi-omics approach, as well as innovative screening strategies and complementing our results with clinical patient samples and data, our goal is to identify new oncogenic transcriptional networks in acute lymphoblastic leukemia (ALL) which will ultimately lead to new targeted treatment strategies for patients with this disease

Read more

→ SCHEICH LAB

Our group focuses on translational cancer research. We are dedicated to advancing knowledge in two specific research fields, lymphoid malignancies and the microbiome in cancer patients. Our overarching objective is to elucidate the fundamental mechanisms contributing to the onset of hematologic malignancies, patients' response to established therapeutic modalities and to find novel therapeutic targets. Through state-of-the art technologies such as CRISPR/Cas9 screens, functional proteomics and super resolution microscopy (dSTORM, SIM) we study lymphoma biology. Paired with the genomic and proteomic analysis of patient derived materials, we study disease development and therapy responses to ultimately improve patient outcomes.

Read more

→ RIEGER LAB

We focus our research on basic mechanisms that control normal and disturbed stem cell fate decisions (self-renewal, differentiation, lineage choice, quiescence, metabolism). Clonal architecture, dominance and competition of stem cells in health and disease are studied. Hematopoietic stem cells and their orchestrated differentiation into blood cell lineages are primarily studied. Eary molecular drivers of clonal dominance and their consequences on interorgan communication and disease progression must be understood for early prevention and treatment of hematologic and non-hematologic diseases.  We utilize and develop cutting-edge single cell technologies and bioinformatic analyses and apply them to stem cell systems from mice and humans. MultiOmics single cell sequencing combined with multi-color FACS sorting enable analysis of defined cell identites.

Read more

Research Programs

Our department is embedded in a vibrant research environment, fostering numerous fruitful national and international collaborations. By combining expertise from diverse research sites, we accelerate discoveries in lymphoma, leukemia, and cell therapy research. Through this global network, we are translating cutting-edge findings into clinical advancements.

FOR5643 Herzblut

The DFG-funded Research Unit FOR5643 (HERZBLUT) comprises a strong team of world-leading experts in the fields of hematology and cardiovascular medicine and emerging junior investigators to pair strong life science and medical research experience with sophisticated technologies and advanced research approaches.

CARISMa

The CARISMa research program for innovative cell therapy research is funded from 2025-2028 and aims to elucidate the molecular pathways controlling CAR T-cell activity and study resistance mechanisms mediated by the tumor microenvironment.

BITeAML

The innovation research program Boost Immuno-Therapy for AML (BITeAML) aims at revolutionizing immunotherapy against acute myeloid leukemia. Prof. Thomas Oellerich will be the overall coordinator.

NEWS

Recently Published

  • New ALL guidelines published
    in Blood (05/2024)
    by Gökbuget et al.

    Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
    Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints and outcomes. Aspects of treatment, management of subgroups and specific situations, aftercare, and supportive care are covered in a separate publication. The present recommendation intends to provide guidance for the initial management of adult patients with ALL and to define principles as a basis for future collaborative research.

    Read More

  • New paper published
    in Leukemia (12/2023)
    by Enssle et al.

    Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, whether disease- and therapy-related alterations in immune cells and cytokine-responsiveness contribute to the observed heterogeneous vaccination responses is unclear. Thus, we analyzed peripheral blood mononuclear cells from patients with MM during and after SARS-CoV-2 vaccination and breakthrough infection (BTI) using combined whole-transcriptome and surface proteome single-cell profiling with functional serological and T-cell validation in 58 MM patients. Our results demonstrate that vaccine-responders showed a significant overrepresentation of cytotoxic CD4+ T- and mature CD38+ NK-cells expressing FAS+/TIM3+ with a robust cytokine-responsiveness, such as type-I-interferon-, IL-12- and TNF-α-mediated signaling. Patients with MM experiencing BTI developed strong serological and cellular responses and exhibited similar cytokine-responsive immune cell patterns as vaccine-responders. This study can expand our understanding of molecular and cellular patterns associated with immunization responses and may benefit the design of improved vaccination strategies in immunocompromised patients.

    Read More

  • New paper published
    in Cancer Cell (02/2024)
    by Phelan & Scheich et al.

    Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton’s tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on chronic active BCR signaling to promote oncogenic NF-κB. The MCD genetic subtype, which often acquires mutations in the BCR subunit, CD79B, and in the innate immune adapter, MYD88L265P, typically resists chemotherapy but responds exceptionally to BTK inhibitors.

    However, the underlying mechanisms of response to BTK inhibitors are poorly understood. Herein, we find a non-canonical form of chronic selective autophagy in MCD DLBCL that targets ubiquitinated MYD88L265P for degradation in a TBK1-dependent manner. MCD tumors acquire genetic and epigenetic alterations that attenuate this autophagic tumor suppressive pathway. In contrast, BTK inhibitors promote autophagic degradation of MYD88L265P, thus explaining their exceptional clinical benefit in MCD DLBCL.

  • New paper published
    in Cancer Discovery (08/2023)
    by Scheich et al.

    Glycosylation controls oncogenic B-cell receptor signaling

    Diffuse large B-cell lymphoma (DLBCL) can be subdivided into the activated B-cell (ABC) and germinal center B cell–like (GCB) subtypes. Self-antigen engagement of B-cell receptors (BCR) in ABC tumors induces their clustering, thereby initiating chronic active signaling and activation of NF-κB and PI3 kinase. Constitutive BCR signaling is essential in some GCB tumors but primarily activates PI3 kinase. We devised genome-wide CRISPR–Cas9 screens to identify regulators of IRF4, a direct transcriptional target of NF-κB and an indicator of proximal BCR signaling in ABC DLBCL. Unexpectedly, inactivation of N-linked protein glycosylation by the oligosaccharyltransferase-B (OST-B) complex reduced IRF4 expression. OST-B inhibition of BCR glycosylation reduced BCR clustering and internalization while promoting its association with CD22, which attenuated PI3 kinase and NF-κB activation. By directly interfering with proximal BCR signaling, OST-B inactivation killed models of ABC and GCB DLBCL, supporting the development of selective OST-B inhibitors for the treatment of these aggressive cancers.

    Read More

  • New paper published
    in Cancer Cell (03/2022)
    by Jayavelu & Wolf & Buettner et al.

    The proteogenomic subtypes of acute myeloid leukemia
    Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a comprehensive proteogenomic analysis of bone marrow biopsies from 252 uniformly treated AML patients to elucidate the molecular pathophysiology of AML in order to inform future diagnostic and therapeutic approaches. In addition to in-depth quantitative proteomics, our analysis includes cytogenetic profiling and DNA/RNA sequencing. We identify five proteomic AML subtypes, each reflecting specific biological features spanning genomic boundaries. Two of these proteomic subtypes correlate with patient outcome, but none is exclusively associated with specific genomic aberrations. Remarkably, one subtype (Mito-AML), which is captured only in the proteome, is characterized by high expression of mitochondrial proteins and confers poor outcome, with reduced remission rate and shorter overall survival on treatment with intensive induction chemotherapy. Functional analyses reveal that Mito-AML is metabolically wired toward stronger complex I-dependent respiration and is more responsive to treatment with the BCL2 inhibitor venetoclax.

    Read More

Updates

  • CARISMa Grant (4,8 Mio)
    successfully acquired
    from 2025-2028!

    The collaborative CARISMa research program was successfully acquired for 2025-2028, providing 4.8 million in funding for innovative cell therapy research. The excellence research funding program of the state of Hessen (LOEWE) provides the grant. (Speaker: T. Oellerich)

  • BITeAML funding successfully acquired
    in the 12th DKTK Joint Funding Call
    "INNOVATION 2024"

    The 12th DKTK Joint Funding Call “INNOVATION 2024” is completed. With the DKTK Joint Funding Program line “INNOVATION”, DKTK supports translational research projects of DKTK scientists for up to three years. At least three DKTK partner sites must be involved in the proposed research project. Maximum budget that can be requested in this call is 1.5 Mio €. A total of 35 proposals have been submitted during this call. (Speaker: T. Oellerich)

  • German Lymphoma Alliance 2023 Award
    in Lymphoma Biology
    for Sebastian Scheich ↓

    In 2023, Sebastian Scheich was honored with the German Lymphoma Alliance Award in Lymphoma Biology. This recognition celebrates his outstanding dedication and significant contributions to the field of lymphoma biology.
    His work has not only deepened the understanding of lymphoma biology but also paved the way for novel approaches in their treatment and therapy. This award underscores his commitment and passion for researching and combating this disease.

  • Seer’s Proteograph XT
    available in our proteomics lab

    We’re happy to implement Seer’s nanoparticle-based Proteograph platform for deep plasma proteomics. Our proteomics team already received extensive application training and is looking forward to work with the instrument. Special thanks got to Ryan, Maik, Dave and Helmut from Seer. Image credits: Maik Pruess, Seer Inc.

  • Orbitrap Astral
    arrived in our proteomics lab

    We’re excited to get in touch with Thermo Fisher’s next-generation Tribrid mass spectrometer. Its exceptional combination of sensitivity, speed, and versatility will boost our proteomics workflows, especially for deep plasma and low-input analyses. The instrument has just been deployed to our facilities and is ready to be installed and put into service.

News Archive

  • 3rd Frankfurt Cancer Conference 2024 28-30 August

    The Frankfurt Cancer Conference is a three-day on-site meeting of internationally leading cancer researchers as well as junior scientists and clinical oncologists. The main theme of the conference in 2024 is “Targeting the tumor-host interface”.

    The ongoing translational research activities of the University Cancer Center (UCT) Frankfurt, the German Cancer Consortium (DKTK) in Frankfurt/Mainz and the Frankfurt Cancer Institute (FCI) provide the framework for the conference. International, national and local research activities will be presented with focus on the following topics:

    • Metabolism at the tumor-host interface
    • Targeted cell therapy  
    • Molecular drug discovery  
    • Modulating immune therapy response  
    • Post-transcriptional disease mechanisms
    • Exploitation of the tumor microenvironment

    Read more

  • West German Lymphoma Symposium 24th and 25th of May 2024, Essen

    Launch of the bi-annual West German Lymphoma Symposium, to facilitate the scientific exchange within the region, excite young researchers for lymphoma research, and, most importantly, to further expand our international visibility and outreach.

    The organizing team of the West German Lymphoma Symposium is happy to invite you to be part of our inaugural meeting. The meeting will take place on 24th and 25th of May 2024 in Essen Germany.

    • Deadline Abstract Submission 10th April 2024
    • Symposium 24th and 25th May 2024

  • SFB1530 annual retreat in Estoril

    This year's retreat took place in conjunction with the [7th Translational Research Conference]
    ( https://www.esh.org/conference/7th-translational-research-conference-lymphoid-malignancies )
    on Lymphoid Malignancies, organized by the European School of Haematology (ESH). Owing to the conference's subject, the organization of our annual retreat fit in seamlessly.

    Our consortium did not only use this opportunity to present their data among international leading scientists in the field of B-cell malignancies, but they could also learn from the most recent developments in the biology and therapy thereof. Both early career scientists as well as principal investigators within our CRC were selected to speak at individual sessions and to present their latest findings during the poster session.

    Subsequently, we extensively discussed our own projects and progress over two days, which was packed with fruitful exchange and new, exciting schemes for the coming year.

     

Weiterlesen … Main Page

  • Aufrufe: 12056

Geschrieben von admin am . Veröffentlicht in Uncategorised.

AG Serve

Serve Lab
Molecular
Research

Serve Lab
Molecular
Research

GOETHE UNIVERSITY
GOETHE UNIVERSITY

Latest
News

HOME

RESEARCH

OUR TEAM

STUDENTS & TEACHING

PUBLICATIONS & FUNDING

Welcome to the pages of the Serve lab!

We – a team of highly motivated and trained cell and molecular biologists, biochemists, physicians and clinician scientists - are particularly interested in uncovering targetable molecular mechanisms of clinically relevant biological phenotypes in Acute Myeloid Leukemia (AML) with the goal of discovering novel clues for AML therapy.
To do this, we are using state-of-the-art techniques, including forward genetic CRISPR/Cas9 dependency as well as resistance and sensitizer screens, CRISPR/Cas9-based prime editing to introduce patient-specific oncogene mutations and BH3 profiling to measure apoptotic priming and dependencies in AML cell lines and patient-derived AML blasts.


NEWS

June 2024
Frankfurt Cancer Conference 2024
Targeting the tumor-host interface
28. –30. August 2024
Campus Westend, Casino, Festsaal

www.frankfurtcancerconference.org

May 2024
Philipp Kunik has been awarded a José Carreras-DGHO doctoral scholarship. Congratulation!

February 2024
A warm welcome to Claudia and Nidhi, the two new PhD students in our team.

December 2023
“PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia” is published in Leukemia. Congratulations to Islam Alshamleh and the entire team!

December 2023
Farewell to our dear colleague Dr. Frank Wempe, whom we wish all the best for his retirement!

November 2023
Marcel received his doctorate with magna cum laude! Congratulations Dr. Seibert!

November 2023
“The MYC-Regulated RNA-Binding Proteins hnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival” has been published in Cancers. Congratulations to Marcel Seibert and all co-authors!

October 2023
New DFG Research Unit FOR5643 “HERZBLUT” funded under the leadership of Michael Rieger

September 2023
Verena received her doctorate with magna cum laude! Congratulations Dr. Stolp!

July 2023
Philipp Makowka has received a Clinician Scientist Fellowship from the Mildred Scheel Young Investigator Center Frankfurt which will be funded from May 2024 to December 2025. Our congratulations!


 
 
 
 
 
 
 
 
 
 
 
 

Weiterlesen … AG Serve

  • Aufrufe: 583

Geschrieben von admin am . Veröffentlicht in Uncategorised.

AG Rieger

Rieger Lab
Basic Mechanisms in Stem Cell Biology 

Rieger Lab
Basic Mechanisms
in Stem Cell
Biology

GOETHE UNIVERSITY

HOME

RESEARCH

PUBLICATIONS

OUR TEAM

JOBS

CONTACT

OUR MISSION

Molecular knowledge about stem cell behavior and control propels innovative therapies for dysregulated stem-cell driven diseases. From precision biology to personalized medicine.

Stem cells raise enormous hope and expectations
for regenerative medicine and targeted therapy.
We study the (patho)physiology of blood and colon stem cells during clonal evolution from normal to malignant. Especially early transformative events
and single mutations on their transition into premalignancy are in the center of interest.

Stem cells raise enormous hope and expectations for regenerative medicine and targeted therapy. We study the (patho)physiology of blood and colon stem cells during clonal evolution from normal to malignant. Especially early transformative events and single mutations on their transition into premalignancy are in the center of interest.

 

Stem Cells: Hope for Regenerative Medicine

RIEGER LAB

Research

Open Positions

Postdoc

Scientific Manager (also in part-time)

 

Studying Early Changes in Blood and Colon Stem Cells

RIEGER LAB

Jobs

NEWS

Dec 2024
Marius Külp received Kick-Off Funding from EHA - congrats

Dec 2024
Selected oral presentation at ASH 2024 for Marius Külp - nice story!

Nov 2024
German Health Centers (DZG) Innovative Fund under the guidance of Michael received

May 2024
Adrien positively evaluated by the MSNZ committee – congrats!

Jan 2024
Marius received Postdoc Start-up grant from the Excellence Cluster CPI – well done!

Dec 2023
Tessa received a Travel Grant to ASH from GSCN - congrats!

Oct 2023
New DFG Research Unit FOR5643 “HERZBLUT” under the Michael´s leadership funded

→link

Aug 2023
Alec won the Greg Johnson Award at ISEH - congrats!!


July 2023
Ika defended her thesis
- Magna cum laude! Well done, Dr. Yu


July 2023
Alec nomminated for ISEH New Investigator Award!

→ link

July 2023
Patrizias clinical follow-up study published - well done!

→ link

Oct 2022
Overview article on CHIP by Michael in "Der Internist"

→ link

July 2022
Michael contributed to a transdisciplinary book
on Complexity in Science, Culture and Society

→ link

July 2022
Mick Milsom´s HSC story is out! Cell Stem Cell

→ link

June 2022
Our CHIP team scored again - CHIP and COPD

→ link

March 2022
Michael runs for Directorship at ISEH - go to vote now!

→ link

June 2021
Study published: Transglutaminase 2 promotes
colon cancer cell survival - congrats to Patrizia and Ilaria

→ link

June 2021
Esther defended her thesis - Well done Dr. med.!

→ link

May 2021
Michael published Editorial on CHIP

→ link

March 2021
New study published on clonal hematopoiesis
- big congrats to Katharina

→ link

Jan 2021
Lena successfully defended her thesis -
congrats Dr. Dorsheimer


Nov 2020
Alec Gessner joint the team as PhD student
- welcome Alec!


July 2020
New positions available in the lab!

→ link

June 2020
Fighting COVID19 - support by Goethe Corona Fonds

link

April 2020
Joining the BD MultiOmics Alliance

→ link

March 2020
New PhD Student positions available!

→ link

Jan 2020
New Review on Clonal Hematopoiesis (CHIP) published

→ link

Dec 2019
Frankfurt University highlights
our latest research

→ link

Nov 2019
Lena published bone marrow alterations in CHIP carriers - congrats!

→ link

Oct 2019
Editorial on NATURE paper about stem cell
expansion by Michael

→ link

Oct 2019
Ilaria successfully defended her thesis
- congrats Dr. Lunger


Oct 2019
Rene received MD stipent from the
Jackstädt-Stiftung at the DGHO - congrats!


Sept 2019
Our CHIP Team scored again - EHJ publication!

→ link

May 2019
Christina´s paper about CHIP after autoSCT
published in Cell Reports - congrats!

→ link

Jan 2019
New lab positions available (PhD, Postdoc, TA)


Dec 2018
Clonal hematopoiesis contribute to ischemic
heart failure - published in JAMA Cardiology

→ link

Dec 2018
New TA position available


Dec 2018
New Postdoc position available


Nov 2018
Public Report about Rieger Lab

→ link

Sept 2018
Excellence Cluster Cardio-Pulmonary-Institute funded!

→ link

Aug 2018
Michael invited speaker at ISEH 2018 in Los Angeles


June 2018
New PostDoc position available


Feb 2018
MiRNA-193b in AML - great story published in JCO

→ link

Dec 2017
Bartosch successfully defended his thesis
- congrats Dr. Wojcik


Dec 2017
Bartosch and Fabian published Perspective
Article in ONCOTARGET

→ link

Affiliations

Active Memberships

Weiterlesen … AG Rieger

  • Aufrufe: 997

Weitere Beiträge …

© UNIVERSITY HOSPITAL FRANKFURT/MAIN
All rights reserved.